
Measles Outbreaks Drive Race for New Treatments
As US measles cases rise to multidecade highs amid falling vaccination rates, researchers are developing monoclonal antibody therapies and antiviral drugs to treat infections and protect vulnerable populations. While these treatments could offer short-term protection and aid outbreak control, challenges include manufacturing at scale, costly clinical trials, regulatory hurdles, and whether people will accept non-vaccine interventions, meaning real-world availability could still be years away.













